Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 2
1993 1
1994 1
1995 2
1997 2
1998 6
1999 2
2000 3
2001 2
2002 3
2003 2
2004 3
2005 1
2006 2
2007 2
2008 3
2009 8
2010 6
2011 2
2012 2
2013 4
2014 8
2015 6
2016 9
2017 9
2018 8
2019 6
2020 8
2021 6
2022 4
Text availability
Article attribute
Article type
Publication date

Search Results

102 results
Results by year
Filters applied: . Clear all
Page 1
Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial.
Wang M, Rule S, Zinzani PL, Goy A, Casasnovas O, Smith SD, Damaj G, Doorduijn J, Lamy T, Morschhauser F, Panizo C, Shah B, Davies A, Eek R, Dupuis J, Jacobsen E, Kater AP, Le Gouill S, Oberic L, Robak T, Covey T, Dua R, Hamdy A, Huang X, Izumi R, Patel P, Rothbaum W, Slatter JG, Jurczak W. Wang M, et al. Among authors: panizo c. Lancet. 2018 Feb 17;391(10121):659-667. doi: 10.1016/S0140-6736(17)33108-2. Epub 2017 Dec 11. Lancet. 2018. PMID: 29241979 Free PMC article. Clinical Trial.
The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma.
Moreno L, Perez C, Zabaleta A, Manrique I, Alignani D, Ajona D, Blanco L, Lasa M, Maiso P, Rodriguez I, Garate S, Jelinek T, Segura V, Moreno C, Merino J, Rodriguez-Otero P, Panizo C, Prosper F, San-Miguel JF, Paiva B. Moreno L, et al. Among authors: panizo c. Clin Cancer Res. 2019 May 15;25(10):3176-3187. doi: 10.1158/1078-0432.CCR-18-1597. Epub 2019 Jan 28. Clin Cancer Res. 2019. PMID: 30692097
PD-1/PD-L1 immune checkpoint and p53 loss facilitate tumor progression in activated B-cell diffuse large B-cell lymphomas.
Pascual M, Mena-Varas M, Robles EF, Garcia-Barchino MJ, Panizo C, Hervas-Stubbs S, Alignani D, Sagardoy A, Martinez-Ferrandis JI, Bunting KL, Meier S, Sagaert X, Bagnara D, Guruceaga E, Blanco O, Celay J, Martínez-Baztan A, Casares N, Lasarte JJ, MacCarthy T, Melnick A, Martinez-Climent JA, Roa S. Pascual M, et al. Among authors: panizo c. Blood. 2019 May 30;133(22):2401-2412. doi: 10.1182/blood.2018889931. Epub 2019 Apr 11. Blood. 2019. PMID: 30975638 Free PMC article.
Endogenous Retroelement Activation by Epigenetic Therapy Reverses the Warburg Effect and Elicits Mitochondrial-Mediated Cancer Cell Death.
Fresquet V, Garcia-Barchino MJ, Larrayoz M, Celay J, Vicente C, Fernandez-Galilea M, Larrayoz MJ, Calasanz MJ, Panizo C, Junza A, Han J, Prior C, Fortes P, Pio R, Oyarzabal J, Martinez-Baztan A, Paiva B, Moreno-Aliaga MJ, Odero MD, Agirre X, Yanes O, Prosper F, Martinez-Climent JA. Fresquet V, et al. Among authors: panizo c. Cancer Discov. 2021 May;11(5):1268-1285. doi: 10.1158/2159-8290.CD-20-1065. Epub 2020 Dec 18. Cancer Discov. 2021. PMID: 33355179
Rituximab in dermatology.
España A, Ornilla E, Panizo C. España A, et al. Among authors: panizo c. Actas Dermosifiliogr. 2013 Jun;104(5):380-92. doi: 10.1016/j.adengl.2013.04.002. Epub 2013 May 10. Actas Dermosifiliogr. 2013. PMID: 23665436 Free article. Review. English, Spanish.
Update on posttransplant lymphoproliferative disease.
Martin-Moreno PL, Panizo C. Martin-Moreno PL, et al. Among authors: panizo c. Curr Opin Nephrol Hypertens. 2018 Nov;27(6):440-444. doi: 10.1097/MNH.0000000000000457. Curr Opin Nephrol Hypertens. 2018. PMID: 30157079 Review.
Obinutuzumab in follicular lymphoma.
Martinez-Calle N, Figueroa-Mora R, Villar-Fernandez S, Marcos-Jubilar M, Panizo C. Martinez-Calle N, et al. Among authors: panizo c. Drugs Today (Barc). 2016 Dec;52(12):643-651. doi: 10.1358/dot.2016.52.12.2550578. Drugs Today (Barc). 2016. PMID: 28276536 Review.
[Treatment of venous thromboembolism].
Rocha E, Panizo C, Lecumberri R. Rocha E, et al. Among authors: panizo c. Med Clin (Barc). 2000 Jul 8;115(6):224-35. doi: 10.1016/s0025-7753(00)71516-8. Med Clin (Barc). 2000. PMID: 11002463 Review. Spanish. No abstract available.
102 results